Yinglu Guo: PSA screening test requires wider application in China

www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. Prof. Yinglu Guo (Figure 1), MD, is an academician of Chinese Academy of Engineering, academic leader of Urology and Andrology. He is the honorary president of Peking University First Hospital and honorary director of Institute of Urology, Peking University; Dean of Peking University Urologist Training College and Andrology Center of Peking University First Hospital; Dean of National Urological, male reproductive Cancer Research Center and Ministry of Health Urological, male reproductive Cancer Medical Center; and President of Division of Urologist, Chinese Medical Doctor Association. Prof. Guo is also the Editor-in-Chief of Translational Andrology and Urology (TAU). Prostate cancer is a common malignant tumor in the male genital system and the incidence is relatively high in Europe and in the United States. In China, the incidence of prostate cancer has increased in the past decade. Prostate Specific Antigen (PSA) test is a common screening method for prostatic cancers and it has always been valued by medical experts. However, PSA is controversial in most Western countries and in the United States. . Incidence in Caucasian males is ten times higher than that in Asian males. Research results for Europeans may not be suitable for Chinese. Searching for methods of diagnosis and therapy suitable for Chinese prostate cancer patients is a current task for Chinese professionals. In this interview, we invited Professor Yinglu Guo to share with us his opinions about the current situation and development of prostate cancer and the future of PSA in China. DXY reporter: Prof. Guo, thank you very much for accepting our interview. I would like to ask you several questions about the diagnosis and treatment of prostate cancer. It’s a common malignant tumor of older men and the incidence is high in Europe and in the United States. In the past decade, the prevalence of prostatic cancer in China has increased substantially. What do you think causes this problem? Prof. Guo: It is my pleasure to do the interview with DXY. Prostate cancer used to be one of the most common malignant tumors for the male elderly in developed countries in Europe and in the United States. In China we considered it a minor illness and thus did not pay much attention to it. However, as the society becomes affluent in associated aging population, urbanization, western diet and better diagnostic technology, contributed to the surge in cases of prostate cancer. In Beijing city, prostate cancer patients comprise of the highest percentage of all hospitalized urology patients at Beijing Hospitals. In my opinion, there are three causes. First, the Chinese Featured Interview